Stock VYNE VYNE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report : VYNE Therapeutics Inc.

Highlights VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Market Closed - Nasdaq
Other stock markets
 04:00:00 2023-12-05 pm EST 		Intraday chart for VYNE Therapeutics Inc. 5-day change 1st Jan Change
3.49 USD +3.25% -12.09% +29.26%
Nov. 13 Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000 MT
Nov. 13 VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Highlights

Search
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000
MT
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
VYNE Therapeutics Inc. Announces Positive Data from Phase 1b Trial for Novel Bet Inhibitor VYN201 in Patients with Nonsegmental Vitiligo
CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q2 Revenue $135,000
MT
VYNE Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $99,000
MT
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
VYNE Therapeutics Inc. Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions
CI
VYNE Therapeutics Inc. Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis
CI
VYNE Therapeutics Inc. Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1A Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain Bet Inhibitor Vyn201
CI
VYNE THERAPEUTICS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
CI
VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
CI
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q4 Revenue $6,000
MT
VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201
CI
Vyne Therapeutics Launching 1-for-18 Reverse Stock Split; Shares Drop
MT
VYNE Therapeutics Inc. Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201
CI
VYNE Therapeutics Inc. Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo
CI
VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies

Filters

Announcement Date

Since

Until

  1. Stock
  2. Equities
  3. Stock VYNE Therapeutics Inc. - Nasdaq
  4. News VYNE Therapeutics Inc.
  5. Highlights
As early as today, start finding the best investment opportunities!
Optimize my profits
fermer